Glenmark Pharmaceuticals (NSE:GLENMARK) filed an intimation with NSE and BSE on 7 August 2026, disclosing a schedule of four analyst and institutional investor meetings to be held across Mumbai between 12 August and 17 September 2026, confirming no unpublished price-sensitive information will be shared at any of these events.
Key Highlights
- Glenmark Pharmaceuticals has scheduled four physical investor meetings in Mumbai between 12 August 2026 and 17 September 2026, covering both group and one-on-one formats.
- The participating forums include Emkay Confluence 2026, Motilal Oswal 22nd Annual Investor Conference 2026, Elara India Dialogue 2026, and the Kotak Healthcare Forum.
- The company has explicitly confirmed that no Unpublished Price Sensitive Information will be disclosed at any of the four scheduled meetings, in line with SEBI LODR requirements.
- All meeting dates are subject to change due to exigencies on the part of the investor or the company, as stated in the filing.
About the Company
Glenmark Pharmaceuticals Limited (NSE:GLENMARK), headquartered in Mumbai, Maharashtra, is an integrated pharmaceutical company operating across branded generics, generics, and specialty segments. The company markets products in more than 80 countries and maintains active research and development operations focused on dermatology, respiratory, and oncology therapeutic areas. Its CIN is L24299MH1977PLC019982.
Announcement in Detail
Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Glenmark Pharmaceuticals filed Reference No. 43/26-27 on 7 August 2026, detailing four upcoming engagements with analysts and institutional investors. The first meeting is at the Emkay Confluence 2026 in Mumbai on 12 August 2026, accommodating both group and one-on-one interactions. This is followed by the Motilal Oswal 22nd Annual Investor Conference 2026, also in Mumbai, on 17 August 2026, again in a physical format covering both meeting types.
Two further events are confirmed for September 2026. The Elara India Dialogue 2026 is scheduled for 1 September 2026 in Mumbai, while the Kotak Healthcare Forum is set for 17 September 2026, also in Mumbai. All four are physical meetings offering both group and one-on-one formats. The filing was signed by Rashmi Khandelwal, Company Secretary and Compliance Officer, holding the designation ACS-28839, confirming the intimation was made on behalf of the company in accordance with applicable listing norms.
Impact on Investors
Investors will note that this filing is a disclosure of meeting schedules under SEBI LODR norms and does not carry any financial guidance, earnings revision, or strategic announcement. The filing shows that the company has explicitly confirmed compliance with UPSI restrictions, meaning no material non-public information will be communicated at any of these forums. Shareholders will observe that the breadth of engagement, spanning four prominent investor conferences hosted by Emkay, Motilal Oswal, Elara, and Kotak, reflects ongoing institutional outreach activity that is standard practice for a listed pharmaceutical company of Glenmark's scale.
The disclosed terms indicate that while the meetings are subject to rescheduling, the company has committed to keeping exchanges informed of any changes, preserving transparency. No dilution, pledge change, or financial restructuring is involved in this filing, and the Investment Relevance is accordingly assessed as Low/Medium.
Sector / Market Context
India's pharmaceutical sector remains one of the most actively covered by domestic and foreign institutional investors. According to SEBI data, the healthcare and pharma segment consistently attracts significant FPI interest, with the sector featuring prominently at major annual investor conferences hosted by brokerages. Industry body the Indian Pharmaceutical Alliance notes that India is the world's third-largest producer of pharmaceuticals by volume, underpinning the level of institutional engagement that companies like Glenmark routinely maintain through structured investor outreach programmes.